Ligand selectivity for the acetylcholine binding site of the rat alpha4beta2 and alpha3beta4 nicotinic subtypes investigated by molecular docking.
The homology models of the extracellular domains of the neuronal alpha4beta2 (pdb code: 1ole) and ganglionic alpha3beta4 (pdb code: 1olf) rat nicotinic acetylcholine receptor (nAChR) subtypes were refined and energetically minimized. In this work, a series of nAChR ligands (1-15) were docked into the modeled binding cavity of both receptors. High-affinity, toxic ligands such as epibatidine (1) and dechloroepibatidine (2) docked into cluster 1 with the charged tertiary amino group, forming a pi-cation interaction with Trp 147 on the (+) side of the alpha4 subunit and establishing a characteristic H-bond with the Lys 77 on the (-) side of the beta2 subunit. The nontoxic ligands such as 33bMet (3), (S)-A-85380 (4), and acetylcholine (6) docked into cluster 2 with the same pi-cation interaction but with the rest of the molecule occupying a different moiety of the binding pocket. Molecular docking into the alpha3beta4 subtype showed that both enantiomers of 1 (1a and 1b) are representative templates for ligands with affinity toward this ganglionic nAChR subtype. The ranking scores of the docked molecules confirm the existence of structure-dependent subtype selectivity and shed light on the design of specific and selective alpha4beta2 nAChR subtype ligands.
Bisson
William H
WH
Center for Radiopharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Paul Scherrer Institute, Rämistrasse 100,CH-8091 Zürich, Switzerland.
Scapozza
Leonardo
L
Westera
Gerrit
G
Mu
Linjing
L
Schubiger
P A
PA
D000109:Acetylcholine / Q000737:chemistry* / Q000378:metabolism; D000818:Animals; D001384:Azetidines / Q000737:chemistry; D001665:Binding Sites; D001667:Binding, Competitive; D001921:Brain / Q000378:metabolism; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity; D002460:Cell Line; D018360:Crystallography, X-Ray; D006860:Hydrogen Bonding; D066298:In Vitro Techniques; D007555:Isoxazoles / Q000737:chemistry; D008024:Ligands; D051379:Mice; D008958:Models, Molecular; D009419:Nerve Tissue Proteins / Q000737:chemistry* / Q000378:metabolism; D009865:Oocytes / Q000378:metabolism; D011725:Pyridines / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity; D011759:Pyrrolidines / Q000737:chemistry; D051381:Rats; D011978:Receptors, Nicotinic / Q000737:chemistry* / Q000378:metabolism; D012908:Snails; D013237:Stereoisomerism; D013816:Thermodynamics; D014981:Xenopus
C116733:3-(2-(pyrrolidinyl)methoxy)pyridine; C104288:A 85380; D001384:Azetidines; D019086:Bridged Bicyclo Compounds, Heterocyclic; D007555:Isoxazoles; D008024:Ligands; D009419:Nerve Tissue Proteins; D011725:Pyridines; D011759:Pyrrolidines; D011978:Receptors, Nicotinic; C403530:nicotinic receptor alpha3beta4; C403531:nicotinic receptor alpha4beta2; C088383:3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole; C082748:epibatidine; D000109:Acetylcholine